English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn a study publishing December 20 in Nature Cancer, UCSF researchers found that phenotype switching, as opposed to genetic evolution, may be the escape mechanism that explains the failure of precision therapies to date. They found that some cells shift to a mesenchymal, radiation-resistant phenotype (state) as a stress response following standard therapy.
Tag: Glioma
Unraveling the biology behind aggressive pediatric brain tumor reveals potential new treatment avenue
Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer. The team developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, which allowed them to study the tumor’s biology in the presence of a functional immune system, revealing a promising outlook for long-term survival.
ASTRO issues clinical guideline on radiation therapy for IDH-mutant glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma. Evidence-based recommendations outline the multidisciplinary planning and delivery techniques to manage this subset of central nervous system (CNS) tumors.
Sylvester Leads Study on New Treatment Option for Brain Tumor that Relapses or Fails to Respond to Standard of Care
Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School…
Dynamic cells linked to brain tumor growth and recurrence
Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists have long known about the variety of cells within a brain tumor, the ways these tumors grow has relied on the understanding that the cells are static, unmoving and relatively fixed.
A nanoparticle and inhibitor trigger the immune system, outsmarting brain cancer
Scientists at the University of Michigan fabricated a nanoparticle to deliver an inhibitor to brain tumor in mouse models, where the drug successfully turned on the immune system to eliminate the cancer. The process also triggered immune memory so that a reintroduced tumor was eliminated—a sign that this potential new approach could not only treat brain tumors but prevent or delay recurrences.
Study Sheds Light on Mechanism of Liposome Accumulation in Tumors
Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.
New immunotherapy target discovered for malignant brain tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Study Identifies Exposure to Common Food-Borne Pathogen Linked to Rare Brain Cancer
A new study suggests a link between toxoplasma gondii (T. gondii) infection and the risk of glioma, a type of brain cancer, in adults. The report, appearing in the International Journal of Cancer, finds that people who have glioma are more likely to have antibodies to T. gondii (indicating that they have had a previous infection) than a similar group that was cancer free.
New Treatment Approach for a Common Glioma Subtype Shows Promise in Animal Models
A combination approach to treating a common subtype of glioma — which includes metabolic reprogramming and immunotherapy — led to complete tumor regression in 60% of study mice.
New Biomarkers for Glioma Treatment Response
Biomarkers using mass cytometry can assess patient response to an emerging vaccine for a specific pediatric brain tumor, according to a recent multi-center study published in the Journal of Clinical Investigation.
Ludwig Lausanne Study Charts the Immune Landscape of Multiple Brain Cancers
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.
Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
Study Uncovers Unexpected Connection Between Gliomas, Neurodegenerative Diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer’s, as a biomarker for glioma development.